Description

(6,8-Dibromo-3-Methyl-4-Oxo-3,4-Dihydro-Quinazolin-2-Ylsulfanyl)-Acetic Acid is a high-purity, advanced pharmaceutical intermediate with a distinct brominated quinazolinone core structure. This compound matters for its role as a critical building block in the synthesis of novel, potent drug candidates, particularly in oncology and targeted therapy research. Pharmaceutical R&D laboratories and fine chemical manufacturers need this material for developing next-generation small molecule inhibitors and other bioactive compounds.

Application

• Pharmaceutical Intermediate: A key precursor in the synthesis of novel quinazolinone-based kinase inhibitors and other targeted therapeutic agents.
• Oncology Drug Discovery: Used in research and development of potential anti-cancer compounds due to its brominated heterocyclic scaffold.
• Medicinal Chemistry Research: Serves as a versatile scaffold for structure-activity relationship (SAR) studies and lead optimization in drug discovery programs.
• Biochemical Probe Synthesis: Employed in creating specialized molecular tools for studying enzyme function and cellular signaling pathways.
• Fine Chemical Synthesis: Utilized in multi-step organic syntheses to introduce the functionalized quinazolinone moiety into more complex molecules.
• Contract Manufacturing (CMO/CDMO): Supplied to contract research and manufacturing organizations for cGMP production of active pharmaceutical ingredients (APIs).

Basic Information

Product Name	(6,8-Dibromo-3-Methyl-4-Oxo-3,4-Dihydro-Quinazolin-2-Ylsulfanyl)-Acetic Acid
CAS No.	886501-04-8
Molecular Formula	C₁₁H₈Br₂N₂O₃S
Molecular Weight	408.06 g/mol
Synonyms	2-[(6,8-Dibromo-3-methyl-4-oxo-3,4-dihydroquinazolin-2-yl)thio]acetic acid; (6,8-Dibromo-3-methyl-4-oxo-3,4-dihydroquinazolin-2-yl)sulfanylacetic acid; 2-((6,8-Dibromo-3-methyl-4-oxo-3,4-dihydroquinazolin-2-yl)thio)acetic acid; Quinazolin-2-ylthioacetic acid derivative; DBMOQSA; Contact for additional synonyms.
EINECS	Contact for details

Quality Control

Our (6,8-Dibromo-3-Methyl-4-Oxo-3,4-Dihydro-Quinazolin-2-Ylsulfanyl)-Acetic Acid is manufactured under strict quality management systems. Each batch undergoes rigorous analytical testing, including HPLC for purity and identity confirmation via NMR and mass spectrometry, to ensure it meets the stringent requirements for pharmaceutical R&D. Certificates of Analysis (COA) with full traceability are provided with every shipment.

Storage

Preserve in a tightly closed container, protected from light. Store in a cool, dry, and well-ventilated place at a controlled room temperature (15-25°C). Due to its hygroscopic (moisture-sensitive) nature, the container must be kept tightly sealed after opening to prevent degradation from atmospheric moisture.

Specification

Item	Specification
Appearance	White to off-white crystalline powder
Identification (IR)	Conforms to reference spectrum
Identification (HPLC)	Retention time matches reference standard
Purity (HPLC)	≥ 98.0%
Water Content (KF)	≤ 0.5%
Residue on Ignition	≤ 0.1%
Heavy Metals	≤ 10 ppm

Note: Specifications can be tailored. Please contact us for the detailed technical data sheet of a specific grade.